Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029

Stock Information for Elutia Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Elutia Inc.

Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th
Elutia to Participate in the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference & the H.C. Wainwright 28th Annual Global Investment Conference
Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc.
Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch
Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results
Elutia Secures $15 Million Loan Financing from Avenue Capital Group to Fund NXT-41x Launch in $1.5 Billion Plastic and Reconstructive Surgery Market
Elutia to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026
Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.